Valvular heart disease associated with fenfluramine-phentermine
Open accessThe DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Fenfluramine and phentermine have been individually approved as anorectic agents by the Food and Drug Administration (FDA). When used in combination the drugs may be just as effective as either drug alone, with the added advantages of the need for lower doses of each agent and perhaps fewer side effects. Although the combination has not been approved by the FDA, in 1996 the total number of prescriptions in the United States for fenfluramine and phentermine exceeded 18 million. METHODS: We identified valvular heart disease in 24 women treated with fenfluramine-phentermine who had no history of cardiac disease. The women presented with cardiovascular symptoms or a heart murmur. As increasing numbers of these patients with similar clinical features were identified, there appeared to be an association between these features and fenfluramine-phentermine therapy. RESULTS: Twenty-four women (mean [+/-SD] age, 44+/-8 years) were evaluated 12.3+/-7.1 months after the initiation of fenfluramine-phentermine therapy. Echocardiography demonstrated unusual valvular morphology and regurgitation in all patients. Both right-sided and left-sided heart valves were involved. Eight women also had newly documented pulmonary hypertension. To date, cardiac surgical intervention has been required in five patients. The heart valves had a glistening white appearance. Histopathological findings included plaque-like encasement of the leaflets and chordal structures with intact valve architecture. The histopathological features were identical to those seen in carcinoid or ergotamine-induced valve disease. CONCLUSIONS: These cases arouse concern that fenfluramine-phentermine therapy may be associated with valvular heart disease. Candidates for fenfluramine-phentermine therapy should be informed about serious potential adverse effects, including pulmonary hypertension and valvular heart disease.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Early weight loss medications, such as fenfluramine (Fen-Phen) and sibutramine, were withdrawn due to severe cardiovascular and psychiatric side effects [3,4].”
From Obesity: Clinical Impact, Pathophysiology, Complications, and Modern Innovations in Therapeutic Strategies (2025) · cites this paper as [3]
In the citing paper
“While effective (average 10–15% weight loss), fenfluramine was withdrawn in 1997 after studies linked it to valvular heart disease and pulmonary hypertension [3].”
From Obesity: Clinical Impact, Pathophysiology, Complications, and Modern Innovations in Therapeutic Strategies (2025) · cites this paper as [3]
In the citing paper
“While effective (average 10–15% weight loss), fenfluramine was withdrawn in 1997 after studies linked it to valvular heart disease and pulmonary hypertension [3].”
From Obesity: Clinical Impact, Pathophysiology, Complications, and Modern Innovations in Therapeutic Strategies (2025) · cites this paper as [3]
In the citing paper
“Certainly, starvation, very-low-calorie diets, liquid protein diets, and obesity surgeries have been associated with prolongation of the QTc interval and increased risk of malignant dysrhythmias (1), and various pharmacologic agents have either limited efficacy or considerable toxicity (70 -72).”
From Obesity and Cardiovascular Disease (2009) · cites this paper as [70]
Citations
Cites
Appetite-suppressant drugs and the risk of primary pulmonary hypertension
Abenhaim, L., Moride, Y., Brenot, F., Rich, S., Benichou, J., Kurz, X., Higenbottam, T., Oakley, C., Wouters, E., Aubier, M., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199608293350901 · Cited by 1,162
Carcinoid heart disease. Clinical and echocardiographic spectrum in 74 patients.
Pellikka, P. A., Tajik, A. J., Khandheria, B. K., Seward, J. B., Callahan, J. A., Pitot, H. C., & Kvols, L. K. (1993) · Circulation · doi:10.1161/01.cir.87.4.1188 · Cited by 614
Robiolio, P. A., Rigolin, V. H., Wilson, J. S., Harrison, J. K., Sanders, L. L., Bashore, T. M., & Feldman, J. M. (1995) · Circulation · doi:10.1161/01.cir.92.4.790 · Cited by 406
Doppler Echocardiography: Theory, Instrumentation, Technique, and Application
NISHIMURA, R. A., MILLER, F. A., CALLAHAN, M. J., BENASSI, R. C., SEWARD, J. B., & TAJIK, A. J. (1985) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(12)60540-0 · Cited by 263
Primary pulmonary hypertension and fenfluramine use.
Brenot, F., Herve, P., Petitpretz, P., Parent, F., Duroux, P., & Simonneau, G. (1993) · Heart · doi:10.1136/hrt.70.6.537 · Cited by 251
Weir, E. K., Reeve, H. L., Huang, J. M. C., Michelakis, E., Nelson, D. P., Hampl, V., & Archer, S. L. (1996) · Circulation · doi:10.1161/01.cir.94.9.2216 · Cited by 218
Klein, A. L., Burstow, D. J., Tajik, A. J., Zachariah, P. K., Taliercio, C. P., Taylor, C. L., Bailey, K. R., & Seward, J. B. (1990) · Journal of the American Society of Echocardiography · doi:10.1016/s0894-7317(14)80299-x · Cited by 213
Valve Disease Associated with Ergot Alkaloid Use: Echocardiographic and Pathologic Correlations
Redfield, M. M., Nicholson, W. J., Edwards, W. D., & Tajik, A. J. (1992) · Annals of Internal Medicine · doi:10.7326/0003-4819-117-1-50 · Cited by 156
Self-citationHormonal responses to fenfluramine in depressed and control subjects
Mitchell, P. B., & Smythe, G. A. (1990) · Journal of Affective Disorders · doi:10.1016/0165-0327(90)90008-v · Cited by 99
Irreversible pulmonary hypertension after treatment with fenfluramine.
McMurray, J. J. V., Bloomfield, P. M., & Miller, H. (1986) · BMJ · doi:10.1136/bmj.292.6515.239-a · Cited by 50
Research works printed but not linked: 4
- Heuer L, 1978, Chir Prax, 23, 497
- Tajik AJ, 1978, Mayo Clin Proc, 53, 271
- Thorson AH, 1958, Acta Med Scand Suppl, 334, 99
- Morita T, 1983, Am Rev Respir Dis, 127, 747
Cited by
Items 901–1,000 of 1,001
Anti-obesity drug use before professional treatment in Taiwan.
Liou, T., Wu, C., Chien, H.-C., Lin, W., Lee, W., & Chou, P. (2007) · PubMed · Cited by 13
Reversal of Phen-Fen associated valvular regurgitation documented by serial echocardiography
Vagelos, R. H., Jacobs, M. B., Popp, R. L., & Liang, D. H. (2002) · Journal of the American Society of Echocardiography · doi:10.1067/mje.2002.117864 · Cited by 13
The Role Of Cell Biology And Leaflet Remodeling In The Progression Of Heart Valve Disease
Xu, S., & Grande-Allen, K. J. (2010) · Methodist DeBakey Cardiovascular Journal · doi:10.14797/mdcj-6-1-2 · Cited by 13
Dopamine agonists and valvular heart disease
Cheung, D. S., & Heaney, A. P. (2009) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0b013e32832d9f64 · Cited by 13
The use of animal models in expression pharmacogenomic analyses
Rothberg, B. E. G. (2001) · The Pharmacogenomics Journal · doi:10.1038/sj.tpj.6500008 · Cited by 13
Moltke, L. L., Greenblatt, D. J., Ciraulo, D. A., Grassi, J. M., Granda, B. W., Duan, S. X., Harmatz, J. S., & Shader, R. I. (1998) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199808000-00015 · Cited by 13
Adverse neuropsychiatric events associated with dexfenfluramine and fenfluramine
McCann, U. D., Eligulashvili, V., & Ricaurte, G. A. (1998) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/s0278-5846(98)00063-3 · Cited by 13
“These drugs are known to increase the risk for primary pulmonary hypertension (Rubin, 1997), and recently were withdrawn from the market in the United States due to concerns that they may lead to development of cardiac valvular disease (Connolly et al., 1997).”
BackgroundDrug-Related Valvular Heart Disease: Here We Go Again: Will We Do Better This Time?
Rahimtoola, S. H. (2002) · Mayo Clinic Proceedings · doi:10.4065/77.12.1275 · Cited by 13
Ren, A., Zhu, X., Lehmann, J., Kasem, M., Schrader, T. O., Dang, H., Le, M., Frazer, J. M., Unett, D. J., Grottick, A. J., et al. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c02923 · Cited by 12
Blaustein, A., & Ramanathan, A. (1998) · Cardiology Clinics · doi:10.1016/s0733-8651(05)70031-x · Cited by 12
Real-World Experience of the Efficacy and Safety of Phentermine Use in Adolescents: A Case Series
Ibrahim, A. I. A., Mendoza, B., Stanford, F. C., & Malhotra, S. (2022) · Childhood Obesity · doi:10.1089/chi.2022.0147 · Cited by 12
Primary prevention of cardiovascular disease in women
Gray, M. P., Vogel, B., Mehran, R., Leopold, J. A., & Figtree, G. A. (2024) · Climacteric · doi:10.1080/13697137.2023.2282685 · Cited by 14
“The complex pathogenesis, as well as physiological and psychologic impacts, of obesity have historically resulted in many proposed interventions, with both positive and grave cardiovascular consequences [48,49].”
BackgroundBenfluorex (Mediator®) et atteintes valvulaires
Tribouilloy, C. M., Jeu, A., Maréchaux, S., Jobic, Y., Ruşinaru, D., & Andréjak, M. (2011) · La Presse Médicale · doi:10.1016/j.lpm.2011.09.001 · Cited by 14
Imported Compounded Diet Pill Use Among Brazilian Women Immigrants in the United States
Cohen, P. A., McCormick, D., Casey, C. G., Dawson, G. F., & Hacker, K. A. (2007) · Journal of Immigrant and Minority Health · doi:10.1007/s10903-007-9099-x · Cited by 12
“(1 = very unsatisfied, 3 = satisfied, and 5 = very satisfied) and then dichotomized into unsatisfied [1, 2] and satisfied [3, 4, 5].”
BackgroundDesbuards, N., Antier, D., Rochefort, G. Y., Apfeldorfer, C. S., Schenck, E., Hanton, G. C., & Hyvelin, J.-M. (2008) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2008.11.025 · Cited by 12
“Withdrawal of these anorectic drugs from sale was further prompted by report of carcinoid-like heart valve lesions in patientswhohad taken fenfluramine andphentermine (Connolly et al., 1997; Loke et al., 2002).”
BackgroundBenfluorex-induced mitral stenosis: A misknown etiology
Jobic, Y., ETIENNE, Y., Bruneval, P., & Ennezat, P. (2014) · International Journal of Cardiology · doi:10.1016/j.ijcard.2014.08.110 · Cited by 12
Kim, K., & Park, S. W. (2012) · The Korean Journal of Obesity · doi:10.7570/kjo.2012.21.4.197 · Cited by 13
Pergolide Associated Cardiac Valvulopathy Based on Ontario Administrative Data
Zadikoff, C., Duong-Hua, M., Sykora, K., Marras, C., Lang, A. E., & Rochon, P. A. (2008) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/s0317167100008593 · Cited by 12
“Number of DINs a Median (Range) 10 (1-38) 8 (0-56) 6(0-34)”
Bénard‐Laribière, A., Noïze, P., Girodet, P., Lassalle, R., Dureau‐Pournin, C., Droz‐Perroteau, C., Fourrier‐Réglat, A., Salvo, F., Bezin, J., & Pariente, A. (2018) · Therapies · doi:10.1016/j.therap.2018.12.007 · Cited by 12
An up-to-date evaluation of lorcaserin hydrochloride for the treatment of obesity
Tchang, B. G., Abel, B., Zecca, C., Saunders, K. H., & Shukla, A. P. (2019) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2019.1685496 · Cited by 12
“The 5HT2B receptor is expressed on cardiac valves; prior AOMs fenfluramine and dexfenfluramine, which were nonselective serotonin receptor agonists, were found to cause valvulopathies due to agonistic effects at the 5HT2B receptor [25,26].”
BackgroundEntomotoxicology: Drugs, Toxins, and Insects
Byrd, J. H., & Peace, M. R. (2011) · Wiley eBooks · doi:10.1002/9781118062241.ch14 · Cited by 12
Cabergoline Treatment in Invasive Giant Prolactinoma
Al-Subaie, S., & Almalki, M. (2014) · Clinical Medicine Insights Case Reports · doi:10.4137/ccrep.s15790 · Cited by 12
Ramiscal, J. A. B., & Jatoi, A. (2012) · Current Oncology Reports · doi:10.1007/s11912-012-0236-x · Cited by 12
Statistical Practice as Argumentation: A Sketch of a Theory of Applied Statistics
Hodges, J. S. (1996) · Springer eBooks · doi:10.1007/978-1-4612-2414-3_2 · Cited by 12
A botanical approach to managing obesity
Ghosh, D. K. (2009) · Research Online (University of Wollongong) · Cited by 12
Weight Loss for the Obese: Panacea or Pound-Foolish?
Gaesser, G. A. (2004) · Quest · doi:10.1080/00336297.2004.10491812 · Cited by 12
Whigham, L. D., Dhurandhar, N. V., Rahko, P. S., & Atkinson, R. L. (2006) · International Journal of Obesity · doi:10.1038/sj.ijo.0803498 · Cited by 12
Malak, J., Singer, A., & Reid, B. (1998) · The Journal of Alternative and Complementary Medicine · doi:10.1089/acm.1998.4.131 · Cited by 12
“Vanherweghem's first approach only fo cused on herbs, until Connolly (Connolly et al., 1997) reported cardiac valve insufficiencies as sociated with dexfenfluramine.”
Dillon, K. A., Putnam, K. G., & Avorn, J. (1997) · PubMed · Cited by 12
Black-Box Warnings of Antiseizure Medications: What is Inside the Box?
Wahab, A., & Iqbal, A. (2023) · Pharmaceutical Medicine · doi:10.1007/s40290-023-00475-x · Cited by 11
Can we win the war on obesity with pharmacotherapy?
Gotthardt, J. D., & Bello, N. T. (2016) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2016.1232164 · Cited by 12
Millett, D., & Pach, S. (2021) · Epilepsy & Behavior Reports · doi:10.1016/j.ebr.2021.100461 · Cited by 11
“but was withdrawn following reports of cardiac valve disease in treated patients [20].”
BackgroundRecent advances in drug delivery systems based on natural and synthetic polymes for treating obesity
Xiao, M., Wang, Z., Li, C., Zhang, K., Hou, Z., Sun, S., & Yang, L. (2024) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2024.129311 · Cited by 11
Barateau, L., Baillieul, S., Andréjak, C., Béquignon, É., Boutouyrie, P., Dauvilliers, Y. A., Gagnadoux, F., Geoffroy, P. A., Micoulaud‐Franchi, J., Montani, D., et al. (2024) · Respiratory Medicine and Research · doi:10.1016/j.resmer.2024.101105 · Cited by 16
Calcifications in Benfluorex-Induced Valve Heart Disease: A Misknown Association
Plurien, F., Bruneval, P., Jobic, Y., Iung, B., & Ennezat, P. (2015) · Cardiology · doi:10.1159/000369128 · Cited by 11
Medications for Weight Reduction
Bray, G. A. (2011) · Medical Clinics of North America · doi:10.1016/j.mcna.2011.06.009 · Cited by 12
Neural circuits of eating behaviour: Opportunities for therapeutic development
Clifton, P. G. (2017) · Journal of Psychopharmacology · doi:10.1177/0269881117738629 · Cited by 14
“The selective serotonin reuptake inhibitor, fenfluramine, was also withdrawn due to side effects, including an association with cardiac valvulopathy (Connolly et al., 1997).”
BackgroundTreating obesity in patients with cardiovascular disease: the pharmacotherapeutic options
Andrew, C. A., Saunders, K. H., Shukla, A. P., & Aronne, L. J. (2019) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2018.1561867 · Cited by 11
“required hospitalization, as compared to fenfluraminephentermine, which was typically associated with symptomatic valvulopathy within 1 year of treatment [9].”
BackgroundGroshong, S. D., Tomashefski, J. F., & Cool, C. D. (2008) · Springer eBooks · doi:10.1007/978-0-387-68792-6_28 · Cited by 11
Carabello, B. A. (2007) · Springer eBooks · doi:10.1007/978-1-84628-715-2_15 · Cited by 11
Aristolochic acid nephropathy after Chinese herbal remedies
Vanherweghem, J., Debelle, F., Muniz‐Martinez, M., & Nortier, J. (2003) · Springer eBooks · doi:10.1007/1-4020-2586-6_29 · Cited by 11
“However, the attention was drawn to the role of appetite suppressants in the development of valvular heart diseases [ 26 ].”
BackgroundValvulopathie réversible et traitement par pergolide
CALOMNE, V., DUPUIS, M., Müller, T., & KEMPINERE, F. (2004) · Revue Neurologique · doi:10.1016/s0035-3787(04)70850-4 · Cited by 11
Nakagawa, Y., Tayama, S., Ogata, A., Suzuki, T., & Ishii, H. (2006) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2006.08.024 · Cited by 11
Guidelines for the initiation of obesity treatment
Atkinson, R. L. (1998) · The Journal of Nutritional Biochemistry · doi:10.1016/s0955-2863(98)00033-3 · Cited by 14
Synergistic Anorectic Effect of Dehydroepiandrosterone and d-Fenfluramine on the Obese Zucker Rat
Gillen, G., Porter, J. R., & Svec, F. (1999) · Physiology & Behavior · doi:10.1016/s0031-9384(99)00057-8 · Cited by 12
Sippel, R. S., & Chen, H. R. (2003) · Problems in General Surgery · doi:10.1097/00013452-200309000-00014 · Cited by 11
Pharmacogenomic Profiling in Postmarketing Surveillance: Prospects and Challenges
Issa, A. M. (2003) · Pharmacogenomics · doi:10.1517/phgs.4.5.647.23793 · Cited by 11
McCann, U. D., Szabó, Z. R., Vranešić, M., Seckin, E., Wand, G. S., DuVal, A., Dannals, R. F., & Ricaurte, G. A. (2007) · Molecular Imaging and Biology · doi:10.1007/s11307-007-0082-7 · Cited by 11
Parisi, A. F. (1998) · Annals of Internal Medicine · doi:10.7326/0003-4819-129-11_part_1-199812010-00013 · Cited by 11
Pigliasco, F., Cafaro, A., Barco, S., Stella, M., Mattioli, F., Riva, A., Mancardi, M. M., Lattanzi, S., Bandettini, R., Striano, P., et al. (2024) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2024.116174 · Cited by 11
Serotonin neurons integrate GABA and dopamine inputs to regulate meal initiation
Conde, K., Wong, H., Fang, S., Li, Y., Yu, M., Deng, Y., Liu, Q., Fang, X., Wang, M., Shi, Y., et al. (2024) · Metabolism · doi:10.1016/j.metabol.2024.156099 · Cited by 10
Sellayah, D., & Sikder, D. S. (2013) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12276 · Cited by 11
Efficacy and safety of fenfluramine in patients with Dravet syndrome: A meta‐analysis
Zhang, L., Li, W., & Wang, C. (2020) · Acta Neurologica Scandinavica · doi:10.1111/ane.13387 · Cited by 10
Fenfluramine in clinical practice: new therapy option for Dravet and Lennox–Gastaut syndromes
Muhle, H., Kurlemann, G., Lehmann, I., Hamer, H. M., Mayer, T., Potschka, H., Schubert‐Bast, S., Strzelczyk, A., & Pringsheim, M. (2024) · Clinical Epileptology · doi:10.1007/s10309-023-00646-5 · Cited by 11
Willemen, M. J. C., Mantel-Teeuwisse, A. K., Straus, S. M. J. M., Leufkens, H. G. M., Egberts, T. C. G., & Sturkenboom, M. (2009) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1759 · Cited by 10
Pharmacotherapy for weight loss
Rueda‐Clausen, C. F., & Padwal, R. S. (2014) · BMJ · doi:10.1136/bmj.g3526 · Cited by 13
Creation of a free, Internet-accessible database: the Multiple Target Ligand Database
Chen, C., He, Y., Wu, J., & Zhou, J. (2015) · Journal of Cheminformatics · doi:10.1186/s13321-015-0064-8 · Cited by 11
Vaduganathan, M., & Prasad, V. K. (2015) · European Journal of Heart Failure · doi:10.1002/ejhf.457 · Cited by 10
Outcome Measures, Interim Analyses, and Bayesian Approaches to Randomized Trials
Brown, A., Schriger, D. L., & Barrett, T. W. (2010) · Annals of Emergency Medicine · doi:10.1016/j.annemergmed.2009.09.027 · Cited by 11
Gut Peptide Agonism in the Treatment of Obesity and Diabetes
Grandl, G., Novikoff, A., DiMarchi, R. D., Tschöp, M. H., & Müller, T. D. (2019) · Comprehensive physiology · doi:10.1002/cphy.c180044 · Cited by 11
A new era in gut hormone-based pharmacotherapy for people with obesity
Firman, C., & Batterham, R. L. (2022) · Proceedings of The Nutrition Society · doi:10.1017/s0029665122002695 · Cited by 10
Warnock, J. N., Gamez, C. A. P., Metzler, S. A., Chen, J., Elder, S. H., & Liao, J. (2010) · PubMed · Cited by 10
Sharp, D., & McNamee, D. (1999) · The Lancet · doi:10.1016/s0140-6736(05)74874-1 · Cited by 10
Linne, Y. M., & Rössner, S. (2004) · Clinics in Dermatology · doi:10.1016/j.clindermatol.2004.01.008 · Cited by 11
Scheen, A. J., & Luyckx, F. (1999) · Acta chirurgica Belgica · doi:10.1080/00015458.1999.12098465 · Cited by 13
Role of the serotonergic system in appetite and ingestion control
Lee, M. D., & Clifton, P. G. (2020) · Handbook of behavioral neuroscience · doi:10.1016/b978-0-444-64125-0.00027-x · Cited by 11
Pharmacological Promiscuity and Molecular Properties
Peters, J. (2012) · Wiley eBooks · doi:10.1002/9781118098141.ch3 · Cited by 10
Myxomatous Degenerative Mitral Valve Disease: An Update
Disatian, S. (2010) · The Thai Journal of Veterinary Medicine · doi:10.56808/2985-1130.2218 · Cited by 10
“Fen/Phen valvulopathy in humans has been attributed to the combination of a serotonin agonist effect by fenfluramine and monoamine oxidase inhibition by phentermine (Connally et al., 1997).”
BackgroundRuffoli, R., Soldani, P., Pasquali, L., Ruggieri, S. A., Paparelli, A., & Fornai, F. (2008) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1432.017 · Cited by 11
Nakagawa, Y., Suzuki, T., KAMIMURA, H., & Nagai, F. (2005) · Archives of Toxicology · doi:10.1007/s00204-004-0635-3 · Cited by 10
“1995), valvular heart disease (Connolly et al. 1997), and neurotoxicity (Ricaurte et al.”
BackgroundHPLC OF (±)-FENFLURAMINE AND PHENTERMINE IN PLASMA AFTER DERIVATIZATION WITH DANSYL CHLORIDE
Kaddoumi, A., Nakashima, M. N., Wada, M., Kuroda, N., Nakahara, Y., & Nakashima, K. (2001) · Journal of Liquid Chromatography & Related Technologies · doi:10.1081/jlc-100000326 · Cited by 10
Unger, P., Nortier, J., Martinez, M. C. M., Plein, D., Vandenbossche, J. L., Vereerstraeten, P., & Vanherweghem, J. L. (2003) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfg083 · Cited by 10
Safety of Anti-Obesity Drugs Approved for Long-Term Use
Kim, K. K. (2015) · The Korean Journal of Obesity · doi:10.7570/kjo.2015.24.1.17 · Cited by 10
Greaves, P. (2007) · Elsevier eBooks · doi:10.1016/b978-044452771-4/50008-0 · Cited by 10
Rossi, A., Bertagnolli, G., Cicoira, M., Golia, G., Zanolla, L., Santini, F., Cemin, C., Ferrario, G., & Zardini, P. (2003) · Clinical Cardiology · doi:10.1002/clc.4960261207 · Cited by 10
Obesity pharmacology: past, present, and future
Kushner, R. F., & Manzano, H. (2002) · Current Opinion in Gastroenterology · doi:10.1097/00001574-200203000-00011 · Cited by 11
Pulmonary hypertension as a result of drug therapy
Higenbottam, T., Laude, L., Emery, C., & Essener, M. (2004) · Clinics in Chest Medicine · doi:10.1016/s0272-5231(03)00133-3 · Cited by 10
Chinese Herbs Nephropathy or the Evils of Nature
de Strihou, C. V. Y., & Martínez–Maldonado, M. (1998) · American Journal of Kidney Diseases · doi:10.1016/s0272-6386(14)70018-6 · Cited by 10
Ni, W., Wilhelm, C. S., Bäder, M., Murphy, D. L., Lookingland, K. J., & Watts, S. W. (2005) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.087080 · Cited by 11
“The highly effective anorexigen ( )-fenfluramine (Redux) was widely prescribed for the treatment of obesity until it was associated with primary pulmonary hypertension (Abenhaim et al., 1996) and aortic valvular disease (Connolly et al., 1997).”
Anti-obesity Drugs: From Animal Models to Clinical Efficacy
Dourish, C. T., Wilding, J. P. H., & Halford, J. C. G. (2008) · Elsevier eBooks · doi:10.1016/b978-0-12-373861-5.00028-x · Cited by 12
Diet and pharmacologic therapy of obesity to modify atherosclerosis
Jones, P. H. (2000) · Current Atherosclerosis Reports · doi:10.1007/s11883-000-0065-5 · Cited by 10
“This so-called Fen-Phen regimen was alleged to cause primarily aortic valvular insufficiency, and led to the voluntary withdrawal of fenfluramine and dexfenfluramine [ 51 ].”
BackgroundCitrome, L. (2010) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2010.02501.x · Cited by 10
Digital Necrosis Associated with Dexfenfluramine
Marinella, M. A., & Berrettoni, B. A. (1997) · New England Journal of Medicine · doi:10.1056/nejm199712113372415 · Cited by 10
Importance of Pharmacology Knowledge by Dieticians
Mestres, C., & Duran, M. (2009) · Current Nutrition & Food Science · doi:10.2174/157340109787314749 · Cited by 9
“However, several pitfalls have been occurred in the use of drug for weight loss, and some of them have been taken off the market due to its adverse reactions: thyroid hormonehyperthyroidism; amphetamines-abuse, fenfluramine- cardiac valvular abnormalities, phenylpropanolamine- cardiovascular problems [20, 21].”
BackgroundCapulli, A. K., MacQueen, L. A., O’Connor, B. B., Dauth, S., & Parker, K. K. (2016) · Cardiovascular Pathology · doi:10.1016/j.carpath.2016.04.004 · Cited by 10
Combination treatment to CONQUER obesity?
Shah, K., & Villareal, D. T. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60518-7 · Cited by 9
CLASH OF THE TITANS: WHEN THE MARKET AND SCIENCE COLLIDE
Marsh, L., & Hardwick, D. F. (2012) · Cited by 9
Pharmacologic management of obesity
Kushner, R. F. (2011) · Pediatric Blood & Cancer · doi:10.1002/pbc.23366 · Cited by 9
MTLD, a Database of Multiple Target Ligands, the Updated Version
Chen, C., Wu, M. Y., Cen, S., Wu, J., & Zhou, J. (2017) · Molecules · doi:10.3390/molecules22091375 · Cited by 9
Challenging obesity, diabetes, and addiction: the potential of lorcaserin extended release
Hurt, R. T., Mundi, M. S., & Ebbert, J. O. (2018) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s126855 · Cited by 10
“Previously approved medications in this class (fenfluramine and dexfenfluramine) were removed from the market due to association with valvular heart disease likely due to agonist activity of the 5HT 2B receptors, which have increased expression in cardiac tissue.(21,22) Unlike these earlier 5HT medications, lorcaserin…”
BackgroundCE: The Obesity Epidemic, Part 2 Nursing Assessment and Intervention
Budd, G. M., & Peterson, J. A. (2014) · AJN American Journal of Nursing · doi:10.1097/01.naj.0000459630.15292.d5 · Cited by 12
Endodontics in Systemically Compromised Patients
Wynne, C. (2017) · Springer eBooks · doi:10.1007/978-3-319-60997-3_12 · Cited by 9
Prevalence, Consequences, Causes and Management of Obesity
Tappia, P. S., & Defries, D. M. (2020) · Springer eBooks · doi:10.1007/978-3-030-35358-2_1 · Cited by 11
A Review of the Combination of Phentermine and Topiramate Extended-Release for Weight Loss
Steffen, K. J., & Kolotkin, R. L. (2012) · Combination Products in Therapy · doi:10.1007/s13556-012-0003-1 · Cited by 10
Mitral and aortic valvular disease associated with benfluorex use.
ETIENNE, Y., Jobic, Y., Frachon, I., Fatemi, M., Castellant, P., & Quintin‐Roué, I. (2011) · PubMed · Cited by 9
Dravet syndrome—toward an optimal and disease-specific treatment
Schoonjans, A., & Ceulemans, B. (2021) · Clinical Epileptology · doi:10.1007/s10309-021-00399-z · Cited by 9
Receptor systems: Will mining the receptorome yield novel targets for pharmacotherapy?
Roth, B. L. (2005) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2005.06.013 · Cited by 10
Serotonin: It's Possible to Have Too Much of a Good Thing
Stahl, S. M. (1997) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v58n1201 · Cited by 9
“Recent reports indicate that similar cardiac valvular pathology is associated with fenfluramine administration.(7) It is not known whether this is a chance association or whether f e n f l u r a m i n e causes this damage.”
BackgroundKatsilambros, N. L. (2000) · European Journal of Internal Medicine · doi:10.1016/s0953-6205(00)00063-7 · Cited by 12
Orforglipron: A Novel Oral GLP-1 Agonist for the Treatment of Obesity and Diabetes
Pillai, A. A., Sharma, A. M., Krayem, H., Frishman, W. H., & Aronow, W. S. (2025) · Cardiology in Review · doi:10.1097/crd.0000000000001139 · Cited by 3
Metadata
- Authors
- Connolly, H. M., Crary, J. L., McGoon, M. D., Hensrud, D. D., Edwards, B. S., Edwards, W. D., & Schaff, H. V.
- Affiliations
- Mayo Clinic (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 1997-08-28
- Volume
- 337
- Issue
- 9
- Pages
- 581-588
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2134362869
- Cited by
- 1,632
- References
- 14
- Citations by year
- 2026: 23 · 2025: 23 · 2024: 26 · 2023: 43 · 2022: 32 · 2021: 40 · 2020: 35 · 2019: 39 · 2018: 42 · 2017: 55 · 2016: 54 · 2015: 58 · 2014: 51 · 2013: 55 · 2012: 59
- FWCI
- 72.34
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Valve Diseases and Treatments
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Issues in Pregnancy
- Keywords
- valvular heart disease, pulmonary hypertension, anorectic agents, women, adverse drug reactions
- MeSH terms
- Adult, Aortic Valve Insufficiency, Appetite Depressants, Drug Combinations, Female, Fenfluramine, Heart Valve Diseases, Humans, Hypertension, Pulmonary, Middle Aged, Mitral Valve, Mitral Valve Insufficiency, Phentermine, Tricuspid Valve Insufficiency, Ultrasonography
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.